CollPlant Biotechnologies Ltd. (CLGN) News
Filter CLGN News Items
CLGN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest CLGN News From Around the Web
Below are the latest news stories about COLLPLANT BIOTECHNOLOGIES LTD that investors may wish to consider to help them evaluate CLGN as an investment opportunity.
CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced financial results for the third quarter ended September 30, 2023, and provided a corporate update on its programs. |
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATIONCollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that it will report financial results for the third quarter of 2023 on Wednesday, November 29, 2023, before the market open. The Company will then host a conference call and webcast to discuss its financial results and corporate updates on November 29 at 10 |
Will CollPlant Biotechnologies (NASDAQ:CLGN) Spend Its Cash Wisely?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
CollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal FillerCollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that the U.S. Patent and Trademark Office has granted a patent that covers CollPlant's photocurable dermal filler product candidate, being developed for the aesthetics market. |
Shareholders in CollPlant Biotechnologies (NASDAQ:CLGN) are in the red if they invested three years agoMany investors define successful investing as beating the market average over the long term. But in any portfolio... |
CollPlant Biotechnologies Joins the United Nations Global Compact, The World's Largest Corporate Sustainability InitiativeCollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that it has joined the United Nations Global Compact, the world's largest initiative for sustainable and responsible corporate governance. As a new member of this voluntary leadership platform, CollPlant strengthens its commitment to operate sustainably as |
CollPlant to Present at the H.C. Wainwright Annual Growth ConferenceCollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that it will participate at the H.C Wainwright Annual Growth Conference, to be held from September 11-13, 2023 in New York, NY. Eran Rotem, CollPlant's Deputy CEO and Chief Financial Officer, is scheduled to present on Tuesday, September 12th at 4:00 PM ET. |
Results: CollPlant Biotechnologies Ltd. Beat Earnings Expectations And Analysts Now Have New ForecastsCollPlant Biotechnologies Ltd. ( NASDAQ:CLGN ) just released its quarterly report and things are looking bullish... |
CollPlant Biotechnologies Announces Second Quarter Financial Results For 2023 with Revenues of $10.2 MillionCollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced financial results for the second quarter ended June 30, 2023, and provided a corporate update on its programs. |
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 SECOND QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATIONCollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that it will report financial results for the second quarter of 2023 on Thursday, August 24, 2023, before the market open. The Company will then host a conference call and webcast to discuss its financial results and corporate updates on August 24th at 10:0 |